Dalla Lana School of Public Health, University of Toronto, Ontario, M5T 3M7, Canada.
Regen Med. 2011 Nov;6(6 Suppl):163-6. doi: 10.2217/rme.11.67.
Developing countries such as China, India and Brazil are making large investments in the stem cell field. Here we argue that hands-on involvement in the field by these countries is essential if the products developed are going to be locally relevant, affordable and appropriate. However, stem cells are a high-risk investment and any global health impacts are still likely to be far off. Even if they are eventually successful, better clinical oversight and measures to ensure access are required for stem cells to have a substantial and equitable impact.
发展中国家，如中国、印度和巴西，正在干细胞领域投入大量资金。我们认为，如果要开发出具有本地相关性、可负担和适宜的产品，这些国家必须积极参与该领域。然而，干细胞是一项高风险投资，其对全球健康的影响仍可能遥遥无期。即使最终取得成功，也需要更好的临床监督和措施来确保获取途径，干细胞才能产生重大和公平的影响。
